LJI scientists uncover the structure and function of Inmazeb, the first FDA-approved drug for Ebola virus infection
La Jolla Institute for ImmunologyInmazeb (REGN-EB3), developed by Regeneron, is a three-antibody cocktail designed to target the Ebola virus glycoprotein. The drug was first approved for clinical use in October 2020, but its exact mechanism of action has remained unclear.